Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20229844 | 0.89 | ROCK1 (0.45) | NPC1RAB9ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL17452599 | 0.87 | ROCK2 (0.54) | NPC1RAB9ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL19902378 | 0.85 | TSHR (0.62) | NPC1RAB9ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL19902546 | 0.82 | ROCK2 (0.61) | NPC1RAB9AROCK1ROCK2 | |
| SCHEMBL19902547 | 0.82 | ROCK1 (0.56) | RAB9AROCK1ROCK2TSHRLMNA | |
| SCHEMBL19902318 | 0.78 | ROCK1 (0.55) | NPC1RAB9AROCK1ROCK2 | |
| SCHEMBL17452763 | 0.77 | ROCK2 (0.49) | NPC1RAB9ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL19902689 | 0.77 | ROCK2 (0.46) | NPC1RAB9ASMN1; SMN2ROCK1ROCK2 | |
| SCHEMBL19902453 | 0.77 | ROCK2 (0.61) | ROCK1ROCK2 | |
| SCHEMBL19902449 | 0.76 | ROCK1 (0.59) | NPC1RAB9AROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | NPC1 2709/4885RAB9A 564/4885SMN1; SMN2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.